Dustin Samples

Cancer Nursing Today nonprod

A group of researchers from several institutions in Denmark recently sought to understand the effects of different cytoreductive therapies for myeloproliferative neoplasms (MPN) on quality of life by self-reported MPN Symptom Assessment Form (MPN-SAF) score.Therapies investigated were hydroxyurea (HU) and pegylated interferon-alpha2a/b (INF&alpha;-2a/2b). Newly diagnosed patients were randomized to treatment by age &gt;60 years (HU, INF&alpha;-2a, INF&alpha;-2b) or age &le;60 years (INF&alpha;-2a or INF&alpha;-2b).MPN-SAF scores were recorded at baseline and at 4, 8, 12, 18, 24, 30, and 36 months. Scores were compared in 2 sets: HU &gt;60 years versus INF&alpha; &gt;60 years and INF&alpha;-2a versus INF&alpha;-2b. These comparisons avoided age bias.At 36 months, only 96 of an initial 199 patients who completed the MPN-SAF at baseline had completed an MPN-SAF. The overall discontinuation of therapy rate at 36 months was 48%. A total of 179 patients completed at least 1 MPN-SAF during the follow-up period.Total symptom burden (reported as total symptom score [TSS]) increased in all treatment groups from baseline to 4 months. No significant differences existed in TSS between any of the comparison groups. The only group to experience statistically significant increase in TSS was the HU &gt;60 group, and only at 36-month follow-up.During the study period, patients receiving HU reported increases in symptoms of fatigue, abdominal pain or discomfort, sexuality problems, itching, and bone pain. Patients who received INF&alpha; reported increases in symptoms of fatigue, early satiety, abdominal pain, abdominal discomfort, inactivity, headache, concentration problems, numbness, dizziness, insomnia, sexuality problems, cough, and itching.At the end of the study period, fatigue was the most-reported symptom, and 63% of patients who completed the 36-month MPN-SAF reported 1 or more moderate or severe symptoms.Some patients who had symptoms at baseline did report a reduction in symptoms during the study period (HU &gt;60: 23% vs IFN&alpha; &gt;60: 30%; IFN&alpha;-2a: 33% vs IFN&alpha;-2b: 38%), though the reduction was not statistically significant.Knudsen TA, Hansen DL, Ocias LF, et al. Quality of life and symptom burden of patients with MPN during treatment with hydroxyurea or pegylated interferon-alpha2: results from a randomized controlled trial. Abstract #743. Presented at the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Louisiana.

Quality of Life for Patients With MPN Varies by Treatment

Do cytoreductive therapies affect quality of life for patients with MPN in different ways?

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe